$-0.09 EPS Expected for Cytosorbents Corp (CTSO)

October 28, 2017 – By Linda Rogers

Investors sentiment decreased to 0.73 in Q2 2017. Its down 2.41, from 3.14 in 2017Q1. It turned negative, as 4 investors sold Cytosorbents Corp shares while 11 reduced holdings. 3 funds opened positions while 8 raised stakes. 1.87 million shares or 55.22% less from 4.19 million shares in 2017Q1 were reported.
Jpmorgan Chase And Co holds 285 shares or 0% of its portfolio. Morgan Stanley invested in 2,507 shares or 0% of the stock. Fortaleza Asset Mgmt holds 0.1% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 12,875 shares. 50,000 were reported by Raymond James And Associates. Barclays Public Limited Company stated it has 2 shares. Northern Trust invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Creative Planning invested in 6,200 shares. State Street Corp has invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Peak6 Invs Ltd Partnership owns 21,231 shares. The Florida-based Aviance Capital Ltd has invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Grp Inc Incorporated One Trading L P has invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Wisconsin-based Skylands Cap Limited Com has invested 0.35% in Cytosorbents Corp (NASDAQ:CTSO). California Employees Retirement holds 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 46,100 shares. Blackrock Incorporated holds 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 112,174 shares. Geode reported 0% stake.

Since May 15, 2017, it had 7 insider buys, and 0 selling transactions for $80,608 activity. Chan Phillip P. had bought 6,300 shares worth $25,200. 1,500 shares were bought by BATOR MICHAEL G., worth $6,180 on Friday, June 9. On Monday, May 15 the insider BLOCH KATHLEEN P. bought $4,341. Capponi Vincent had bought 2,500 shares worth $10,000. Mortensen Eric R. also bought $10,100 worth of Cytosorbents Corp (NASDAQ:CTSO) shares.

Analysts expect Cytosorbents Corp (NASDAQ:CTSO) to report $-0.09 EPS on November, 6.They anticipate $0.02 EPS change or 18.18 % from last quarter’s $-0.11 EPS. After having $-0.04 EPS previously, Cytosorbents Corp’s analysts see 125.00 % EPS growth. The stock increased 2.48% or $0.15 on October 27, reaching $6.2. About 161,086 shares traded. Cytosorbents Corp (NASDAQ:CTSO) has declined 4.26% since October 28, 2016 and is downtrending. It has underperformed by 20.96% the S&P500.

Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage

Among 6 analysts covering CytoSorbents (NASDAQ:CTSO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 11 analyst reports since October 29, 2015 according to SRatingsIntel. On Tuesday, May 24 the stock rating was initiated by Maxim Group with “Buy”. Aegis Capital maintained the shares of CTSO in report on Tuesday, May 30 with “Buy” rating. The stock of Cytosorbents Corp (NASDAQ:CTSO) has “Buy” rating given on Monday, July 17 by Maxim Group. Aegis Capital initiated the shares of CTSO in report on Wednesday, October 26 with “Buy” rating. On Tuesday, September 26 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Thursday, October 29 by WBB Securities. The rating was maintained by Maxim Group with “Buy” on Tuesday, August 8. The rating was maintained by Maxim Group with “Buy” on Wednesday, July 5. On Friday, October 7 the stock rating was initiated by B. Riley & Co with “Buy”.

CytoSorbents Corporation is a critical care focused immunotherapy company. The company has market cap of $174.43 million. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. It currently has negative earnings. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Prnewswire.com which released: “CytoSorbents – A Leader in Blood Purification to Treat Deadly Inflammation …” on June 06, 2017, also Prnewswire.com with their article: “Dr. Eric R. Mortensen, MD, Ph.D., Clinical Trial Veteran, Joins CytoSorbents …” published on May 30, 2017, Seekingalpha.com published: “Cytosorbents: A Razor & Razor Blade Story” on June 28, 2017. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Seekingalpha.com and their article: “CytoSorbents’ (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results – Earnings Call …” published on August 08, 2017 as well as Seekingalpha.com‘s news article titled: “Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position” with publication date: August 04, 2017.